Mesothelin and immunotherapy for pancreatic cancer / 中华内分泌外科杂志

ABSTRACT

As one of the most lethal malignancies, pancreatic cancer and its therapy remains a big problem all around the world. With the few candidates for surgery and the poor outcome for chemotherapy, the immunotherapy becomes one important direction. Mesothelin, a membrane protein, expresses at low levels in normal tissues, but is re-expressed at a high frequency in pancreatic cancer, which makes mesothelin an ideal target for immunotherapy.This review summarizes the progression of mesothein-targeted immunotherapy for pancreatic cancer.